Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
Summary
The purpose of this study is to determine if patients with melancholic bipolar II depression are more responsive to lamotrigine than patients with non-melancholic bipolar II depression. To do this, the investigators will re-analyze a previous clinical trial that evaluated lamotrigine as a treatment for bipolar II depression (GSK-SCA100223; NCT00274677).
Timeline
- Start
- 2003-11
- Primary completion
- 2005-08
- Completion
- 2017-12
Outcome
Mixed primary results
registry analysis (superiority test); Lamotrigine - Melancholic Depression vs Placebo - Melancholic Depression vs Lamotrigine - Nonmelancholic Depression vs Placebo - Nonmelancholic Depression; p = .59 NCT02989727 ↗
registry analysis (superiority test); Lamotrigine - Melancholic Depression vs Placebo - Melancholic Depression vs Lamotrigine - Nonmelancholic Depression vs Placebo - Nonmelancholic Depression; p = .84 NCT02989727 ↗
registry analysis (superiority test); Lamotrigine - Melancholic Depression vs Placebo - Melancholic Depression; p = .08 NCT02989727 ↗
registry analysis (superiority test); Lamotrigine - Nonmelancholic Depression vs Placebo - Nonmelancholic Depression; p = .53 NCT02989727 ↗
registry analysis (superiority test); Lamotrigine - Melancholic Depression vs Placebo - Melancholic Depression; p = .02; Cox Proportional Hazard 1.27; Regression, Cox NCT02989727 ↗
registry analysis (superiority test); Lamotrigine - Nonmelancholic Depression vs Placebo - Nonmelancholic Depression; p = .73; Cox Proportional Hazard 1.05; Regression, Cox NCT02989727 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamotrigine | Small molecule | 200 mg | — |